Research hypothesis
The Atlas Hypothesis
ME/CFS as a phenotype-informed failure of biological stress resolution
- Status
- Research hypothesis
- Evidence status
- Hypothesis-generating synthesis
- Clinical status
- Not diagnostic guidance. Not treatment guidance.
- Main limitation
- The temporal sequence from exertion to PEM is not yet established.
Read this first
This page is highly speculative. It is published as brainstorming material and as a starting point for dialog with researchers, clinicians and patient advocates — not as a finding, not as a model the Atlas endorses, and not as guidance for any decision a reader might face. The cautious phrasing throughout (“may”, “could”, “candidate”, “proposed”) is the appropriate epistemic register. Nothing below should be read as established.
Abstract
Post-exertional malaise (PEM) is the defining clinical feature of ME/CFS, but the biological sequence that produces delayed relapse remains unresolved. Current research describes abnormalities across immune function, cellular energy metabolism, autonomic regulation, perfusion physiology and CNS function. These abnormalities are repeatedly discussed across the ME/CFS literature, but most studies measure one system at a time, often at rest. The field lacks a prospective 0–72 hour post-exertional study that measures metabolic, immune, autonomic, perfusion and CNS changes in the same individuals while tracking PEM onset and recovery.
The Atlas Hypothesis proposes a research framework: ME/CFS may involve a persistent baseline vulnerability across immune, metabolic, autonomic, perfusion and CNS systems. In some patients, this vulnerability may follow infection-triggered immune reprogramming and possible regulatory or epigenetic locking. Exertion, cognitive demand, orthostatic stress or sensory stress may then exceed the system’s reduced recovery capacity. PEM emerges when biological stress resolution fails.
This model does not propose one universal linear mechanism. It proposes phenotype-informed convergence: different patients may reach the same clinical endpoint, delayed PEM, through different dominant biological pathways [murovska-2026-myalgic-encephalomyelitis].
1. Why this hypothesis exists
ME/CFS research often asks:
What is abnormal at baseline?
That question is necessary, but insufficient. PEM is a dynamic phenomenon. A patient may appear similar to baseline immediately after activity, then deteriorate hours or days later.
The Atlas Hypothesis reframes the central question:
What fails to normalize after biological stress?
The hypothesis therefore focuses on recovery, resolution and reset rather than only static abnormality.
2. Core claim
ME/CFS may be best studied as a phenotype-informed failure of biological stress resolution in a vulnerable immune-metabolic-autonomic-CNS network.
This is not a proven mechanism. It is a testable research framework.
3. Model overview
The proposed sequence from biological trigger to delayed PEM, with multiple candidate phenotype pathways converging on the same clinical endpoint.
Candidate phenotype pathways: autonomic / preload / perfusion; immune-reset; metabolic-recovery; CNS / neuroinflammatory; and gut-vagal, respiratory or vestibular modifiers.
4. Baseline vulnerability versus exertion-triggered cascade
| Layer | What it means | Evidence status |
|---|---|---|
| Baseline vulnerability | Persistent abnormalities or lowered reserve before exertion | Supported across several domains, but mechanisms vary |
| Stress exposure | Physical, cognitive, orthostatic, sensory or infectious load | Clinically central to PEM |
| Failed resolution | Incomplete return to baseline after stress | Strongly plausible, but not directly mapped across systems |
| PEM endpoint | Delayed relapse in function and symptoms | Clinically established, but biological timing remains unresolved |
The model separates baseline disease state from the PEM cascade. A patient can have baseline abnormalities without those abnormalities alone explaining the delayed crash.
5. Why PEM may be delayed
A purely immediate energy-depletion model is incomplete, because PEM often appears after delay. A purely delayed immune model is also incomplete, because early autonomic and metabolic responses may occur before symptoms peak.
The Atlas Hypothesis proposes a staged but not yet proven sequence:
0–4 hours
Acute compensation, sympathetic activation, early metabolic strain
Inferred
4–12 hours
Possible purinergic / DAMP signaling, immune signaling, failed early reset
Inferred
12–72 hours
Clinical PEM emerges as recovery failure becomes systemic
Observed clinically; mechanism unresolved
No current evidence base establishes this full sequence as fact.
6. Candidate phenotype pathways
The model does not assume that all patients crash through the same pathway.
| Candidate pathway | Phenotype pattern | Evidence | Main uncertainty |
|---|---|---|---|
| Autonomic / preload / perfusion dominant | Orthostatic intolerance, exaggerated heart-rate rise, low perfusion reserve, cognitive worsening upright [schiweck-2026-systematic-literature] | Moderate | Primary driver versus compensatory failure unclear |
| Immune-reset candidate | Post-infectious onset, immune activation, possible viral or autoimmune overlap | Moderate | Serial post-exertional immune recovery data missing |
| Metabolic-recovery candidate | Severe exertional intolerance, prolonged recovery, metabolic abnormalities [naviaux-2016-metabolomics] | Moderate | Early ATP / lactate kinetics not established |
| CNS / neuroinflammatory candidate | Brain fog, sensory overload, cognitive deterioration [penson-2026-evaluating-working] | Low to moderate | Timing and causality remain unclear |
| Gut-vagal modifier | GI symptoms, dysbiosis, vagal / autonomic instability [kim-2026-potential-application] | Low | Causality and subgroup boundaries unclear |
| Respiratory / ventilation modifier | Dyspnea, breathing-pattern disorder, ventilation-perfusion mismatch [wells-2026-breath-mind] | Low to moderate | Relationship to PEM unclear |
| Vestibular / sensory modifier | Dizziness, balance problems, sensory overload, proprioceptive instability [sirotiak-2026-understanding-concussion] | Low to moderate | May be amplifier rather than core PEM pathway |
These are candidate phenotype pathways, not validated biological subtypes.
Phenotype convergence
Different patients may converge on delayed PEM through different dominant pathways. The pathway labels are hypothesis-generating, not validated subtypes.
7. Individual phenotype example
A phenotype with post-infectious onset, low resting heart rate, exaggerated heart-rate rise with light activity, orthostatic or volume intolerance, delayed PEM, cognitive worsening and sensory sensitivity may map most strongly to an autonomic / preload / perfusion-dominant PEM pattern.
This is a phenotype match, not a diagnosis, not a treatment recommendation, and not proof of mechanism.
In this pattern, autonomic / preload / perfusion failure may be the most visible clinical bottleneck, while immune-metabolic dysregulation may be a deeper vulnerability.
8. Evidence map
8.1 Post-exertional functional decline
Two-day CPET findings are among the strongest objective anchors for PEM because they show reduced function after exertional challenge rather than only baseline impairment. This supports the idea of failed recovery, but does not identify the upstream mechanism.
8.2 Metabolic and energy-related findings
Recent multi-system studies report abnormalities in energy metabolism, including altered AMP, ADP, ATP/ADP ratio, NAD-related metabolism and kynurenine pathway markers [naviaux-2016-metabolomics]. These findings support metabolic involvement, but do not prove that ATP failure is the first event after exertion.
8.3 Immune findings
ME/CFS research repeatedly reports immune abnormalities, including NK-cell and T-cell related findings in several cohorts. These findings support immune vulnerability, but serial post-exertional immune-reset data are still missing.
8.4 Autonomic and perfusion findings
Orthostatic intolerance, POTS-like physiology, preload limitations and cerebral blood-flow abnormalities are relevant to PEM, particularly in autonomic / perfusion-dominant phenotypes [schiweck-2026-systematic-literature]. These mechanisms may be primary in some patients and compensatory or downstream in others.
8.5 CNS findings
Cognitive dysfunction, sensory sensitivity and limited neuroinflammatory findings support CNS involvement [penson-2026-evaluating-working]. The model therefore treats CNS / autonomic regulation as a central node, but not as proven primary cause.
8.6 Possible regulatory or epigenetic locking
Epigenetic findings, including OPRM1-related observations in the Atlas corpus [wyns-2026-hypermethylation-oprm1], may suggest stable regulatory changes. These findings should be treated as candidate signals, not proof of causality.
9. What the model explains
9.1 Normal routine resting labs
The model explains why routine resting tests can be normal: the key abnormality may lie in dynamic recovery after stress, not in static resting measurements.
9.2 Delayed PEM
The model explains delayed PEM as failed stress resolution after initial compensation.
9.3 Heterogeneity
The model explains heterogeneity by allowing different dominant pathways to converge on the same clinical endpoint.
9.4 Chronicity
The model allows for persistent disease through immune, metabolic, autonomic or regulatory set-point changes, without assuming one universal cause.
10. What the model does not prove
This hypothesis does not prove that:
- ATP failure is the first event after exertion
- OPRM1 or any single epigenetic marker causes ME/CFS
- immune reset failure is present in every patient
- autonomic dysfunction is always primary
- neuroinflammation is the main driver in all patients
- all ME/CFS patients share one pathway
- any treatment follows from this framework
This is a research model, not clinical guidance.
11. Main weaknesses
| Weakness | Why it matters |
|---|---|
| No prospective 0–72 hour serial PEM study | The temporal sequence is inferred |
| No direct early ATP / lactate kinetics | The first biological domino remains unknown |
| No serial immune-reset data | Failed immune resolution remains plausible, not established |
| Autonomic findings may be compensatory | Autonomic dysfunction may be bridge or consequence |
| CNS findings may be focal | Diffuse hypoperfusion cannot explain all cognitive patterns |
| Candidate pathways are not validated subtypes | Stratification remains hypothesis-generating |
| Long COVID and ME/CFS overlap but are not identical | Post-COVID findings cannot be automatically generalized [soares-2026-recommended-long] |
12. What would falsify or weaken the hypothesis
| Finding | Impact |
|---|---|
| PEM occurs without measurable recovery failure in any tested biological system | Weakens failed-resolution framework |
| Baseline phenotype does not predict post-exertional pathway or PEM pattern | Weakens phenotype-informed convergence |
| Serial metabolic, immune, autonomic and CNS markers normalize before PEM begins | Weakens delayed biological cascade |
| A single universal mechanism explains most patients across phenotypes | Weakens subtype / convergence model |
| Candidate epigenetic or regulatory markers are inconsistent and unrelated to course | Weakens locking component |
13. Decisive study needed
The decisive next study is not another isolated baseline comparison. It is a prospective, phenotype-stratified, 0–72 hour PEM study.
| Component | Requirement |
|---|---|
| Cohort | Strictly defined ME/CFS with documented PEM, plus matched sedentary controls |
| Baseline stratification | Immune, metabolic, autonomic, CNS / perfusion and symptom phenotype |
| Stress trigger | Standardized exertional, orthostatic or cognitive challenge |
| Timepoints | Baseline, immediate, 4h, 12h, 24h, 48h, 72h |
| Metabolic markers | Lactate, pyruvate, acylcarnitines, ATP / ADP-related markers, NAD-related markers |
| Immune markers | NK function, cytokines, chemokines, immune-cell phenotype |
| Autonomic markers | HRV, beat-to-beat blood pressure, orthostatic response, preload indicators |
| Perfusion / CNS | Cerebral blood flow by TCD, NIRS or imaging |
| Outcome | PEM onset, severity, duration and recovery |
| Primary test | Whether baseline phenotype predicts post-exertional collapse pathway |
14. Final formulation
The Atlas Hypothesis proposes that ME/CFS may be best studied as a phenotype-informed failure of biological stress resolution. A persistent baseline vulnerability across immune, metabolic, autonomic, perfusion and CNS systems may lower the capacity to recover after stress. PEM may emerge when exertion exceeds this reduced reset capacity and the patient collapses through a dominant biological pathway.
The Atlas Hypothesis should be tested, not assumed.
References cited on this page
Each link opens the Atlas evidence page for the underlying study, where the primary paper, classification, and machine-summary disclosure are visible. Citations are illustrative for the framework above; this page does not re-summarise the primary findings of these studies.
- Naviaux et al. (2016) — Metabolic features of chronic fatigue syndrome
- Schiweck et al. (2026) — Treatment of postural orthostatic tachycardia syndrome (POTS): systematic literature review
- Wyns et al. (2026) — Hypermethylation of OPRM1: deregulation of the endogenous opioid pathway in ME/CFS and fibromyalgia
- Penson et al. (2026) — Working memory in ME/CFS: systematic review and meta-analysis
- Kim et al. (2026) — Brain-gut axis-based treatments in Long COVID and ME/CFS: case-based systematic review
- Wells et al. (2026) — Breath and mind connection in young people with post-COVID syndrome: pilot RCT
- Sirotiak et al. (2026) — Concussion in ME/CFS: findings from the 2023 NHIS
- Soares et al. (2026) — Recommended Long COVID outcome measures and clinical-trial design with a focus on PEM
- Murovska et al. (2026) — ME/CFS and fibromyalgia: overlap, differences, and emerging insights
Related Atlas pages
- Methodology — how the Atlas is built, version stamps, limitations.
- Evidence Atlas — searchable index of the underlying studies.
- Glossary — definitions for PEM, evidence levels, and other terms used above.
- Understanding PEM — Atlas guide to post-exertional malaise.
- FAQ
This page is highly speculative. It is published as brainstorming material and as a starting point for dialog — not as a finding, not as a model the Atlas endorses, not as a consensus statement, and not as diagnostic or treatment guidance. Cautious language is intentional: the model should be tested, not assumed.